Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 7.7% – What’s Next?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) traded down 7.7% during trading on Friday. The stock traded as low as $2.55 and last traded at $2.63. Approximately 496,216 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 609,792 shares. The stock had previously closed at $2.85.

Analysts Set New Price Targets

INDP has been the subject of several research analyst reports. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Down 7.7%

The company’s 50 day moving average price is $2.14 and its 200-day moving average price is $2.32. The stock has a market cap of $350.42 million, a P/E ratio of -0.42 and a beta of 0.97.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to stimulate the body’s innate and adaptive immune responses while limiting the toxicity associated with certain bacterial components.

Indaptus’ technology platform uses detoxified bacterial toxins, referred to as “DeTocs,” to activate immune cells. Its lead product candidate, Decoy20, is an investigational combination of detoxified toxins being developed as a potential treatment for solid tumors.